Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Sesame Care vs Bodybuilding Health+

Sesame Care
Graded #5

Higher grade

vs+11
Bodybuilding Health+
Graded #37

Lower grade

The verdict

Sesame Care takes it — 87/100 to 76/100.

Sesame Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBodybuilding Health+ +4
84
88
Dose & formulationSesame Care +8
92
84
Clinical oversightSesame Care +20
94
74
Labs & monitoringSesame Care +16
84
68
FulfillmentSesame Care +2
80
78
Contract termsSesame Care +30
92
62
Sesame Care · left barBodybuilding Health+ · right bar

The numbers

MetricSesame CareBodybuilding Health+
WeighScore87/10076/100
GradeB+C
Scorecard rank#5#37
SemaglutideFrom $149/mo (brand Wegovy pill)From $139/mo
TirzepatideBrand Zepbound (price varies)From $139/mo
CoverageNationwide marketplaceNot disclosed
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Sesame Care

Graded #5 · B+

Strengths

  • Real FDA-approved brand-name access — Wegovy pen and pill, Zepbound, Ozempic, Mounjaro and Rybelsus
  • Established platform (operating since 2018) with LegitScript, BBB accreditation and large third-party review volume
  • You choose the provider and see the price up front — genuine marketplace transparency
  • Oral routes available (Wegovy pill, Rybelsus)

Where it loses points

  • A generalist marketplace, not a dedicated weight-loss program — lighter ongoing hand-holding than a specialist desk
  • Two-part cost (a platform subscription plus the medication) makes the true monthly total harder to compare
  • Brand-name cash prices can run high without insurance
Bodybuilding Health+

Graded #37 · C

Strengths

  • Low, publicly listed bundle pricing — compounded semaglutide and tirzepatide both fall to $139/mo on the 12-month plan (first month $179 sema / $209 tirz)
  • Licensed brand extension of Bodybuilding.com (trademark relationship stated on-site), which lends familiarity vs. anonymous GLP-1 startups
  • Unusually broad menu under one login — GLP-1 plus NAD+ (injection or nasal), sermorelin (injection or sublingual ODT), ED/tadalafil, and a deep peptide catalog
  • Standard telehealth flow with clear FDA/compounding disclaimers — online intake reviewed by independent licensed providers, U.S. compounding-pharmacy fulfillment, free until a provider approves

Where it loses points

  • Compounded and not FDA-approved — not Wegovy/Ozempic or Zepbound/Mounjaro; the site itself states these have not been evaluated by the FDA for safety, effectiveness, or quality
  • Brand-new operator — Dynamo Group LLC launched the storefront around April 2026 with only a thin, mixed ~26-review Trustpilot record (cancellation and billing complaints)
  • All sales final — prescription products are non-returnable, the medical-consult fee is non-refundable, and there are no refunds for dissatisfaction or results
  • Pharmacy and provider network aren't named on the live consumer pages, no LegitScript seal we could verify on-site, and the catalog reaches into investigational Retatrutide and research-grade peptides

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 37 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard